FULCRUM THERAPEUTICS, INC. Additional Paid in Capital, Common Stock
FULCRUM THERAPEUTICS, INC. (FULC) had Additional Paid in Capital, Common Stock of $950.54 million as of 2026-06-30, per its S-4 filed 2026-09-02.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-09-02
- 2026-06-30: Additional Paid in Capital, Common Stock $950.54M.
- 2026-03-31: Additional Paid in Capital, Common Stock $946.92M.
- 2025-12-31: Additional Paid in Capital, Common Stock $943.04M.
- 2025-09-30: Additional Paid in Capital, Common Stock $772.01M.
| Period end | Additional Paid in Capital, Common Stock |
|---|---|
| 2026-06-30 | $950.54M S-4 · filed 2026-09-02 |
| 2026-03-31 | $946.92M 10-Q · filed 2026-04-27 |
| 2025-12-31 | $943.04M S-4 · filed 2026-09-02 |
| 2025-09-30 | $772.01M 10-Q · filed 2025-10-29 |
| 2025-06-30 | $768.59M 10-Q · filed 2025-07-29 |
| 2025-03-31 | $765.41M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $762.25M S-4 · filed 2026-09-02 |
| 2024-09-30 | $759.69M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $755.23M 10-Q · filed 2024-07-31 |
| 2024-03-31 | $750.51M 10-Q · filed 2024-05-13 |
| 2023-12-31 | $744.94M 10-K · filed 2025-02-25 |
| 2023-09-30 | $741.20M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $737.47M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $733.96M 10-Q · filed 2023-05-15 |
| 2022-12-31 | $612.02M 10-K · filed 2024-02-27 |
| 2022-09-30 | $608.49M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $524.25M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $518.60M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $514.36M 10-K/A · filed 2023-06-26 |
| 2021-09-30 | $509.64M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $369.13M 10-Q · filed 2021-08-10 |
| 2021-03-31 | $366.34M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $316.77M 10-K/A · filed 2023-06-26 |
| 2020-09-30 | $308.83M 10-Q · filed 2020-11-10 |
| 2020-06-30 | $306.96M 10-Q · filed 2020-08-11 |
| 2020-03-31 | $239.91M 10-Q · filed 2020-05-13 |
| 2019-12-31 | $237.93M 10-K/A · filed 2023-06-23 |
| 2019-09-30 | $236.78M 10-Q · filed 2019-11-14 |
| 2019-06-30 | $6.45M 10-Q · filed 2019-08-26 |
| 2018-12-31 | $4.45M 10-K · filed 2020-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |